

APPLICATION TRANSMITTAL LETTER

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

☒ "Express Mail" Mailing Label No. EL068 326062 US, Date of Deposit Dec. 10, 1998
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Warren Jackson

(Typed or Printed Name of Person Mailing Paper or Fee)

Wayne

(Signature of Person Mailing Paper or Fee)

Transmitted herewith for filing is the patent application of Li WANG, Lorne A. BABIUK, Andrew A. POTTER and Philip WILLSON for POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS.

Enclosed are:

12 sheet(s) of formal ☒ informal drawing(s).

 A claim for foreign priority under 35 U.S.C. § 119/363 in
 a separate document the declaration.

☒ A claim for priority under 35 U.S.C. § 119(e)(1) in
 a separate document ☒ the declaration.

 A certified copy of the priority document.

 Verified Statement(s) Claiming Small Entity Status.

 Other:


The declaration of the inventor ☒ is enclosed ☒ unsigned.

The fee has been calculated as follows:

A. Basic Application Fee		\$790.00
B. Total Claims 47 - 20 = 27	x \$22.00	594.00
C. Independent Claims 3 - 3 = 0	x \$82.00	0.00
D. If multiple dependent claims present, add	\$270.00	0.00
E. Total Application Fee (Total of A, B, C, & D)	=	1384.00
<hr/>		
F. If verified statement of small entity status is enclosed, reduce Total Application Fee by 50%		NA
G. Application Fee Due (E - F)	=	1384.00
<hr/>		
H. Assignment Recording Fee of \$40.00 if assignment document is enclosed	\$40.00	NA
<hr/>		
I. TOTAL FEE (G + H)		\$1384.00

Respectfully submitted,

Date: 12/10/98

By: 
Roberta L. Robins
Registration No. 33,208

ROBINS & ASSOCIATES
90 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 325-7812
Fax: (650) 325-7823

850121-1309 0000000000

Application for U.S. Letters Patent Entitled

POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS

claiming priority to U.S. provisional patent applications
serial nos. 60/069,233 filed December 11, 1997
and 60/069,750 filed December 16, 1997

by Inventors:

Li WANG
Lorne A. BABIUK
Andrew A. POTTER
Philip WILLSON

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label No. EL 068326 96245
Date of Deposit December 10, 1998

I hereby certify that this paper or fee is being deposited
with the United States Postal Service "Express Mail Post
Office to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Assistant
Commissioner for Patents, Washington, D.C. 20231

Warren Jackson

Typed or Printed Name of Person Mailing Paper or Fee)

W-J

(Signature of Person Mailing Paper or Fee)

Robins & Associates
90 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: 650-325-7812
Facsimile: 650-325-7823

Attorney Docket No. 9000-0040

5 POSTWEANING MULTISYSTEMIC WASTING SYNDROME
 VIRUS FROM PIGS

Cross-Reference to Related Applications

 This application is related to provisional
10 patent application serial nos. 60/069,233 filed December
 11, 1997 and 60/069,750 filed December 16, 1997, from
 which applications priority is claimed under 35 USC
 §119(e) (1) and which applications are incorporated herein
 by reference in their entireties.

15 Technical Field

 The present invention relates generally to
 viruses. More particularly, the present invention
 pertains to the isolation and characterization of new
20 porcine circovirus (PCV) isolates from pigs displaying
 postweaning multisystemic wasting syndrome (PMWS).

Background of the Invention

 Postweaning multisystemic wasting syndrome
25 (PMWS) is a newly emerged disease of pigs. PMWS appears
 to destroy the host immune system and causes a high
 mortality rate in weaned pigs. This disease has a long
 incubation period, typically 3-8 weeks, and affects many
 organs of infected pigs. PMWS-affected piglets often die
30 from respiratory failure and interstitial pneumonia with
 histiocytic cell infiltration.

 Porcine circovirus (PCV) causes worldwide
 infection in swine and is highly contagious. PCV was
 originally detected as a noncytopathic contaminant of
35 porcine kidney (PK15) cell lines. PCV has been

classified into the new virus family Circoviridae. These viruses are small, nonenveloped agents with a single-stranded circular DNA genome.

5 A variety of circoviruses have been identified
in a range of animal species including PCV, chicken
anemia virus (CAV), beak and feather disease virus (BFDV)
of psittacine birds, plant viruses including subterranean
clover stunt virus (SCSV), coconut foliar decay virus
(CFDV) and banana bunch top virus (BBTV). There do not
10 appear to be DNA sequence homologies or common antigenic
determinants among the currently recognized circoviruses.
Todd et al. (1991) *Arch. Virol.* 117:129-135.

Members in the circovirus family have been
shown to cause anemia, immunodeficiency-related diseases
15 and to infect macrophage cells *in vitro*. PCV has only
recently been implicated in PMWS. See, e.g., Ellis et
al. (1998) *Can. Vet. J.* 39:44-51 and Gopi et al. (1997)
Can. Vet. J. 38:385-386. However, the etiologic
association of PCV with PMWS has been questioned due to
20 the ubiquitous presence of PCV in the pig population.
Additionally, experimental infections of pigs with PCV
inocula, derived from contaminated PK15 cell cultures,
have failed to produce clinical disease. See, e.g.,
Tischer et al. (1986) *Arch. Virol.* 91:271-276.

25 Infectious agents of swine, especially viruses,
not only profoundly affect the farming industry, but pose
potential public health risks to humans, due to the
increased interest in the use of pig organs for
xenotransplantation in humans. Previous diagnosis of
30 PMWS disease has been based on histopathological
examination. Accordingly, there is a need for improved
methods of diagnosing the presence of PMWS-associated
pathogens, as well as for preventing PMWS disease.

Disclosure of the Invention

The present invention is based on the discovery of a new virus, designated "PCV Type II" or "PCVII" herein, isolated from homogenized tissues of PMWS-affected piglets. Characterization of the virus shows that it shares common features with the nonpathogenic porcine circovirus obtained from persistently infected PK15 cells, designated "PCV Type I" or "PCVI" herein. The entire DNA genome of a novel PCV variant, PCVII 412, as well as several additional PCVII isolates, have been cloned and sequenced. Portions of these DNA sequences are useful as probes to diagnose the presence of virus in clinical samples, and to isolate other naturally occurring variants of the virus. An understanding of the genomic sequence of PCVII also makes available the polypeptide sequences of the various proteins encoded within the open reading frames of the viral genome and permits production of these peptides or portions thereof which are useful as standards or reagents in diagnostic tests and as components of vaccines. Protective antibodies may also be raised from the proteins and may be produced in polyclonal or monoclonal form.

The availability of the entire PCVII sequence thus permits the design and construction of polypeptides which may either serve as vaccines or diagnostic reagents, or as intermediates in the production of monoclonal antibody (Mab) preparations useful in passive immunotherapy against PMWS, or as intermediates in the production of antibodies useful as diagnostic reagents.

Accordingly, in one aspect, the invention relates to polynucleotides useful for the production of PCVII diagnostics and vaccines derived from the PCVII genome. In one particular embodiment, the polynucleotides are capable of selectively hybridizing to a PCVII nucleotide sequence and comprise at least about 8

contiguous nucleotides derived from, or complementary to, a PCVII sequence depicted in Figures 4A-4C (SEQ ID NO:1, SEQ ID NO:11 and SEQ ID NO:12). In another embodiment, the polynucleotide encodes an immunogenic PCVII

5 polypeptide having at least about 85% identity to a polypeptide selected from the group consisting of a polypeptide derived from (a) ORF 1 (SEQ ID NO:3), (b) ORF 2 (SEQ ID NO:9), (c) ORF 3 (SEQ ID NO:7), (d) ORF 4 (SEQ ID NO:20), (e) ORF 5 (SEQ ID NO:21), (f) ORF 6 (SEQ ID
10 NO:5), and (g) immunogenic fragments of (a)-(f) comprising at least about 5 amino acids. In a particularly preferred embodiment, the polynucleotide encodes the polypeptide of ORF 6 (SEQ ID NO:5), or immunogenic fragments thereof.

15 The invention thus relates to utilizing these polynucleotide sequences or portions thereof as oligomeric probes, for production of peptides which can serve as diagnostic reagents or as vaccine antigens, to the peptides themselves, and to polyclonal and monoclonal
20 antibodies useful in diagnosis and treatment of the disease.

Other aspects of the invention include expression systems which are capable of effecting the production of a desired protein encoded by sequences
25 derived from the complete genome, to recombinant vectors containing such systems or portions thereof, to recombinant host cells transformed with such vectors, to proteins produced by the transformed cells, and to vaccines prepared from such proteins. In addition, the
30 invention relates to peptide sequences representing epitopes encoded by the genome, and to such sequences covalently linked to label or to carrier proteins. Also encompassed by the present invention are the various ORFs of the PCVII genome, as well as the proteins encoded by
35 these ORFs, and portions thereof.

090595-1 0360260

The invention also relates to the methods of preparing polypeptide compositions, such as vaccines and immunodiagnostic compositions, and immunoglobulins, and to immunoassays and kits for assays containing the
5 primers, probes, polypeptides, and/or immunoglobulins. In one embodiment, then, the invention pertains to a method of detecting PCVII antibodies in a biological sample comprising:

- (a) providing a biological sample;
- 10 (b) reacting the biological sample with an immunogenic PCVII polypeptide as described above, under conditions which allow PCVII antibodies, when present in the biological sample, to bind to the PCVII polypeptide to form an antibody/antigen complex; and
- 15 (c) detecting the presence or absence of the complex,

thereby detecting the presence or absence of PCVII antibodies in the sample.

- In another embodiment, the invention is
20 directed to a nucleic acid hybridization assay for detecting PCVII homologous sequences in a biological sample comprising:

- (a) incubating the biological sample with a polynucleotide according to claim 1 under conditions
25 which promote the formation of nucleic acid complexes between the polynucleotide and PCVII nucleic acid present in the biological sample; and
- (b) detecting the complexes containing the polynucleotide.

- 30 These and other aspects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying figures.

Figures 2A-2C depict the nucleotide sequence
5 for the PCVII 412 genome (SEQ ID NO:1). Both senses are
shown. The amino acid sequences corresponding to the
translation products of the various ORFs are also shown
as indicated: ORF 1 (SEQ ID NO:3); ORF 2 (SEQ ID NO:9);
ORF 3 (SEQ ID NO:7); ORF 4 (SEQ ID NO:20); ORF 5 (SEQ ID
10 NO:21); and ORF 6 (SEQ ID NO:5).

Figures 3A-3D are comparisons of amino acid sequences from open reading frames of PCVII 412 versus corresponding open reading frames of PCVI isolated from PK15 cells. Figure 3A shows the amino acid sequence of ORF 1 of PCVII 412 (top line, **SEQ ID NO:3**) compared to the corresponding ORF from PCVI (bottom line, **SEQ ID NO:4**). Figure 3B shows the amino acid sequence of ORF 6 of PCVII 412 (top line, **SEQ ID NO:5**) compared to the corresponding ORF from PCVI (bottom line, **SEQ ID NO:6**). Figure 3C shows the amino acid sequence of ORF 3 of PCVII 412 (top line, **SEQ ID NO:7**) compared to the corresponding ORF from PCVI (bottom line, **SEQ ID NO:8**). Figure 3D shows the amino acid sequence of ORF 2 of PCVII 412 (top line, **SEQ ID NO:9**) compared to the corresponding ORF from PCVI (bottom line, **SEQ ID NO:10**).

Figures 4A-4B are comparisons of the nucleotide sequences of various PCV isolates: PCVI from PK15 cells (SEQ ID NO:2), PCVII 412 (SEQ ID NO:1), PCVII 9741 (SEQ ID NO:11) and PCVII B9 (SEQ ID NO:12).

Figure 5 shows the results of multiplex PCR used for the detection of PCV infection. The assay both identified PCV infection and distinguished between the presence of PCVI and PCVII. Lane 1 is a molecular weight marker. Lanes 2-4 are controls in the order of PCVII,

PCVI and negative. Lanes 5-13 are blood samples collected from piglets from a PMWS-affected herd.

Figure 6 shows the results of multiplex PCR conducted on various tissue samples from a PMWS-affected piglet. Lane 1 in both rows is a molecular weight marker. Lane 2 in the top row is a positive PCVII control while lane 3 is a negative control. The remaining lanes are various tissue samples collected from the PMWS-affected piglet.

Detailed Description

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Vols. I, II and III, Second Edition (1989); *DNA Cloning*, Vols. I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Animal Cell Culture* (R.K. Freshney ed. 1986); *Im-mobilized Cells and Enzymes* (IRL press, 1986); Perbal, B., *A Practical Guide to Molecular Cloning* (1984); the series, *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); and *Handbook of Experimental Immunology*, Vols. I-IV (D.M. Weir and C.C. Blackwell eds., 1986, Blackwell Scientific Publications).

Before describing the present invention in detail, it is to be understood that this invention is not limited to particular DNA, polypeptide sequences or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is

for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more antigens, reference to "an excipient" includes mixtures of two or more excipients, and the like.

The following amino acid abbreviations are used throughout the text:

Alanine: Ala (A)	Arginine: Arg (R)
Asparagine: Asn (N)	Aspartic acid: Asp (D)
Cysteine: Cys (C)	Glutamine: Gln (Q)
Glutamic acid: Glu (E)	Glycine: Gly (G)
Histidine: His (H)	Isoleucine: Ile (I)
Leucine: Leu (L)	Lysine: Lys (K)
Methionine: Met (M)	Phenylalanine: Phe (F)
Proline: Pro (P)	Serine: Ser (S)
Threonine: Thr (T)	Tryptophan: Trp (W)
Tyrosine: Tyr (Y)	Valine: Val (V)

A. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

The terms "PCVII protein," "PMWS protein" or a
5 nucleotide sequence encoding the same, intend a protein
or a nucleotide sequence, respectively, which is derived
from a novel PCVII isolate, as described herein. The
nucleotide sequences of several PCVII isolates are shown
in Figures 4A-4B and the amino acid sequences
10 corresponding to the six identified PCVII ORFs are shown
in Figures 2A-2C. However, a PCVII or PMWS protein, or a
gene encoding the same, as defined herein is not limited
to the depicted sequence.

Further, as used herein, a nucleotide sequence
15 "derived from" a PCVII genome or its complement refers to
a sequence which retains the essential properties of the
illustrated polynucleotide, representing a portion of the
entire sequence from which it is derived, for the purpose
intended. A specific, but nonlimiting, example of such
20 derivation is represented by a sequence which encodes an
identical or substantially identical amino acid sequence,
but, because of codon degeneracy, utilizes different
specific codons; another example is a sequence
complementary to the viral DNA. A probe or
25 oligonucleotide useful in diagnostic tests needs to
retain the complementarity of the sequence shown but may
be shorter than the entire sequence or may skip over
portions of it. However, for use in manipulation or
expression, nucleotide changes are often desirable to
30 create or delete restriction sites, provide processing
sites, or to alter the encoded amino acid sequence in
ways which do not adversely affect functionality. The
terms "Nucleotide sequence" and "polynucleotide" refer
both to ribonucleotide and a deoxyribonucleotide

sequences and include both the genomic strand and its complementary sequence.

5 A sequence "derived from" the nucleotide sequence which comprises the genome of a PCVII isolate therefore refers to a sequence which is comprised of a sequence corresponding to a region of the genomic nucleotide sequence (or its complement), or a combination of regions of that sequence modified in ways known in the art to be consistent with its intended use. These
10 sequences are, of course, not necessarily physically derived from the nucleotide sequence of the gene, but refer to polynucleotides generated in whatever manner which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. For example, regions from
15 which typical DNA sequences can be "derived" include regions encoding specific epitopes. Similarly, a peptide "derived from" a PCVII ORF refers to an amino acid sequence substantially identical to that of these polypeptides or a portion thereof, having the same
20 biological properties as that portion.

Furthermore, the derived protein or nucleotide sequences need not be physically derived from the genes described above, but may be generated in any manner,
25 including for example, chemical synthesis, isolation (e.g., from a PCVII isolate) or by recombinant production, based on the information provided herein. Additionally, the term intends proteins having amino acid sequences substantially homologous (as defined below) to
30 contiguous amino acid sequences encoded by the genes, which display immunological activity.

Thus, the terms intend full-length, as well as immunogenic, truncated and partial sequences, and active analogs and precursor forms of the proteins. Also
35 included in the term are nucleotide fragments of the

060991-109

particular gene that include at least about 8 contiguous
base pairs, more preferably at least about 10-20
contiguous base pairs, and even at least about 25 to 50
or 75 or more contiguous base pairs of the gene. Such
5 fragments are useful as probes, in diagnostic methods,
and for the recombinant production of proteins, as
discussed more fully below.

The terms also include proteins in neutral form
or in the form of basic or acid addition salts depending
10 on the mode of preparation. Such acid addition salts may
involve free amino groups and basic salts may be formed
with free carboxyls. Pharmaceutically acceptable basic
and acid addition salts are discussed further below. In
addition, the proteins may be modified by combination
15 with other biological materials such as lipids and
saccharides, or by side chain modification, such as
acetylation of amino groups, phosphorylation of hydroxyl
side chains, oxidation of sulfhydryl groups,
glycosylation of amino acid residues, as well as other
20 modifications of the encoded primary sequence.

The term therefore intends deletions, additions
and substitutions to the sequence, so long as the
polypeptide functions to produce an immunological
response as defined herein. In this regard, particularly
25 preferred substitutions will generally be conservative in
nature, i.e., those substitutions that take place within
a family of amino acids. For example, amino acids are
generally divided into four families: (1) acidic --
aspartate and glutamate; (2) basic -- lysine, arginine,
30 histidine; (3) non-polar -- alanine, valine, leucine,
isoleucine, proline, phenylalanine, methionine,
tryptophan; and (4) uncharged polar -- glycine,
asparagine, glutamine, cystine, serine threonine,
tyrosine. Phenylalanine, tryptophan, and tyrosine are
35 sometimes classified as aromatic amino acids. For

9000-0040 PATENT

The term "vaccine composition" intends any pharmaceutical composition containing an antigen, which composition can be used to prevent or treat a disease or

The term "epitope" refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site." Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.

An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the composition or vaccine of interest. Usually, an "immunological response" includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells and/or $\gamma\delta$ T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host

The terms "immunogenic" protein or polypeptide refer to an amino acid sequence which elicits an immunological response as described above. An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By "immunogenic fragment" is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., *Epitope Mapping Protocols* in *Methods in Molecular Biology*, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871; Geysen et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:3998-4002; Geysen et al. (1986) *Molec. Immunol.* 23:709-715, all incorporated herein by reference in their entireties. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and

2-dimensional nuclear magnetic resonance. See, e.g.,
Epitope Mapping Protocols, supra.

Synthetic antigens are also included within the
definition, for example, polyepitopes, flanking epitopes,
5 and other recombinant or synthetically derived antigens.
See, e.g., Bergmann et al. (1993) *Eur. J. Immunol.*
23:2777-2781; Bergmann et al. (1996) *J. Immunol.*
157:3242-3249; Suhrbier, A. (1997) *Immunol. and Cell*
Biol. 75:402-408; Gardner et al. (1998) 12th World AIDS
10 Conference, Geneva, Switzerland, June 28-July 3, 1998.

Immunogenic fragments, for purposes of the
present invention, will usually include at least about 3
amino acids, preferably at least about 5 amino acids,
more preferably at least about 10-15 amino acids, and
15 most preferably 25 or more amino acids, of the molecule.
There is no critical upper limit to the length of the
fragment, which could comprise nearly the full-length of
the protein sequence, or even a fusion protein comprising
two or more epitopes of the protein.

20 "Native" proteins or polypeptides refer to
proteins or polypeptides isolated from the source in
which the proteins naturally occur. "Recombinant"
polypeptides refer to polypeptides produced by
recombinant DNA techniques; i.e., produced from cells
25 transformed by an exogenous DNA construct encoding the
desired polypeptide. "Synthetic" polypeptides are those
prepared by chemical synthesis.

A "vector" is a replicon, such as a plasmid,
phage, or cosmid, to which another DNA segment may be at-
30 tached so as to bring about the replication of the at-
tached segment.

A DNA "coding sequence" or a "nucleotide
sequence encoding" a particular protein, is a DNA
sequence which is transcribed and translated into a
35 polypeptide *in vitro* or *in vivo* when placed under the

960977-136660

control of appropriate regulatory elements. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding
5 sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding
10 sequence.

DNA "control elements" refers collectively to promoters, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which
15 collectively provide for the transcription and translation of a coding sequence in a host cell. Not all of these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed and translated.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding
25 sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter and the coding sequence and
30 the promoter can still be considered "operably linked" to the coding sequence.

A control element, such as a promoter, "directs the transcription" of a coding sequence in a cell when RNA polymerase will bind the promoter and transcribe the

A "host cell" is a cell which has been transformed, or is capable of transformation, by an exogenous nucleic acid molecule.

"Homology" refers to the percent identity between two polynucleotide or two polypeptide moieties. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified DNA or polypeptide sequence.

Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available

Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., *supra*; *DNA Cloning, supra*; *Nucleic Acid Hybridization, supra*.

Two nucleic acid fragments are considered to be "selectively hybridizable" to a PCVII polynucleotide, if they are capable of specifically hybridizing to a PCVII nucleic acid or a variant thereof (e.g., a probe that hybridizes to a PCVII nucleic acid but not to polynucleotides from other members of the circovirus family) or specifically priming a polymerase chain reaction: (i) under typical hybridization and wash

conditions, as described, for example, in Sambrook et al., *supra* and *Nucleic Acid Hybridization*, *supra*, (ii) using reduced stringency wash conditions that allow at most about 25-30% basepair mismatches, for example: 2 x
5 SSC, 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, 0.1% SDS, 37°C once, 30 minutes; then 2 x SSC room temperature twice, 10 minutes each, or (iii) selecting primers for use in typical polymerase chain reactions (PCR) under standard conditions (described for
10 example, in Saiki, et al. (1988) *Science* 239:487-491), which result in specific amplification of sequences of PCVII or its variants.

The term "functionally equivalent" intends that the amino acid sequence of a protein is one that will
15 elicit a substantially equivalent or enhanced immunological response, as defined above, as compared to the response elicited by a reference amino acid sequence, or an immunogenic portion thereof.

A "heterologous" region of a DNA construct is
20 an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. Thus, when the heterologous region encodes a viral gene, the gene will usually be flanked by DNA that does not flank the viral
25 gene in the genome of the source virus. Another example of the heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Allelic variation or naturally occurring
30 mutational events do not give rise to a heterologous region of DNA, as used herein.

The term "treatment" as used herein refers to either (i) the prevention of infection or reinfection (prophylaxis), or (ii) the reduction or elimination of
35 symptoms of the disease of interest (therapy).

9000-0040 PATENT

As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, blood, plasma, serum, fecal matter, urine, bone marrow, bile, spinal
5 fluid, lymph tissue and lymph fluid, samples of the skin, external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, organs, biopsies and also samples of *in vitro* cell culture constituents including but not limited to
10 conditioned media resulting from the growth of cells and tissues in culture medium, e.g., recombinant cells, and cell components.

As used herein, the terms "label" and "detectable label" refer to a molecule capable of
15 detection, including, but not limited to, radioactive isotopes, fluorescers, chemiluminescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands (e.g., biotin or haptens) and the like. The term
20 "fluorescer" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used under the invention include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol,
25 NADPH and α - β -galactosidase.

By "vertebrate subject" is meant any member of the subphylum cordata, including, without limitation, mammals such as cattle, sheep, pigs, goats, horses, and man; domestic animals such as dogs and cats; and birds,
30 including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds. The term does not denote a particular age. Thus, adult and newborn animals, as well as fetuses, are intended to be covered.

B. General Methods

Central to the present invention is the discovery of a new circovirus termed "PCVII" herein, isolated from PMWS-affected pigs. The useful materials and processes of the present invention are made possible by the discovery of a family of nucleotide sequences, each containing an entire genome of a novel PCVII virus. The availability of this family of polynucleotides, first, permits the isolation of other members of the genome family which differ by small heterogeneities. Second, it permits the construction of DNA fragments and proteins useful in diagnosis. For example, oligomers of at least about 8-10 nucleotides or more, preferably, oligomers comprising at least about 15-20 nucleotides, are useful as hybridization probes in disease diagnosis. Such probes may be used to detect the presence of the viral genome in, for example, sera of subjects suspected of harboring the virus. Similarly, the genes encoding the proteins can be cloned and used to design probes to detect and isolate homologous genes in other viral isolates.

The PCVII sequences also allow the design and production of PCVII-specific polypeptides which are useful as diagnostic reagents for the presence of antibodies raised against PCVII in serum or blood. Antibodies against these polypeptides are also useful as diagnostics. Because several open reading frames can be deciphered in the context of the complete genome, the primary structures of PCVII-related proteins can be deduced. Finally, knowledge of the gene sequences also enables the design and production of vaccines effective against PCVII and hence useful for the prevention of PMWS and also for the production of protective antibodies.

Sequencing information available from the genome allows the amino acid sequence of the various

900Q-0040 PATENT

As shown in Figure 1, the new virus contains at least six potential open reading frames (ORFs) encoding proteins comprising more than 50 amino acid residues, while PCVI derived from PK15 has seven potential ORFs. The ORFs for representative PCVII isolates occur at the following nucleotide positions, using the numbering of the PCVII isolates shown in Figures 4A-4B:

	ORF 1	51 to 992
	ORF 2	671 to 360
	ORF 3	565 to 389
	ORF 4	553 to 729
5	ORF 5	1016 to 1174
	ORF 6	1735 to 1037

The polypeptides encoded by the six ORFs are shown in Figures 2A-2C.

10 The main cellular targets for PCVII are mononuclear cells in the peripheral blood, likely macrophage cells, although the virus is also found in various tissues and organs in infected animals. The affected macrophages lose their normal function, causing
15 damage to the host immune system, leading to death.

 The cloning and sequencing of the novel circoviruses has provided information about the causative agent of PMWS. As explained above, the sequencing information, as well as the clones and its gene products,
20 are useful for diagnosis and in vaccine development. In particular, PCR and antibody-based diagnostic methods are useful in the diagnosis of the disease and were used herein to specifically identify and differentiate this
25 novel PCVII virus from PCVI derived from persistently infected PK15 cells. The sequencing information is also useful in the design of specific primers, to express viral-specific gene products, to study the viral structure, to generate specific antibodies and to
30 identify virulent genes in porcine circovirus-related diseases.

B.1. Preparation of the PCVII Gene Sequence

 The new viral genomes of PCVII were obtained from viruses isolated from tissue of PMWS-affected pigs.
35 Viral DNA was extracted from variable sources, including

pellets of infected Dulac and Vero cells, peripheral blood buffy-coat cells, tissues from infected animals and serum. DNA was extracted from the samples using techniques discussed more fully in the examples.

5 By comparing the sequence and structural similarity among the known viruses in the circovirus family, a unique primer was designed taking advantage of the complementary sequences of a conserved stem loop structure. One-primer PCR was then performed and the products cloned. Two full-length viral genomes in
10 different orientations inserted into a plasmid vector were completely sequenced in both directions. Additional PCR products were made and sequenced to ensure the fidelity of the primer/stem loop region.

15 Using similar primers, other PCVII isolates, including PCVII 9741, and PCVII B9, were obtained. This appears to be the first time a circovirus has been cloned from viral particles instead of from a replicated form of DNA.

20 The description of the method to retrieve the PCVII genome is, of course, mostly of historical interest. The resultant sequence is provided herein, and the entire sequence, or any portion thereof, could also be prepared using synthetic methods, or by a combination
25 of synthetic methods with retrieval of partial sequences using methods similar to those here described.

B.2. Production of PCVII Proteins

The availability of PCVII genomic sequences
30 permits construction of expression vectors encoding viral polypeptides and antigenically active regions thereof, derived from the PCVII genome. Fragments encoding the desired proteins can be obtained from cDNA clones using conventional restriction digestion or by synthetic
35 methods and are ligated into vectors, for example,

0920961-1109
SECRET-19660260

containing portions of fusion sequences such as
 β -galactosidase. Any desired portion of the PCVII genome
containing an open reading frame can be obtained as a
recombinant protein, such as a mature or fusion protein,
5 or can be provided by chemical synthesis or general
recombinant means.

It is readily apparent that PCVII proteins
encoded by the above-described DNA sequences, active
fragments, analogs and chimeric proteins derived from the
10 same, can be produced by a variety of methods.
Recombinant products can take the form of partial protein
sequences, full-length sequences, precursor forms that
include signal sequences, mature forms without signals,
or even fusion proteins (e.g., with an appropriate leader
15 for the recombinant host, or with another subunit antigen
sequence for another pathogen).

Gene libraries can be constructed and the
resulting clones used to transform an appropriate host
cell. Colonies can be pooled and screened using
20 polyclonal serum or monoclonal antibodies to the PCVII
protein.

Alternatively, once the amino acid sequences
are determined, oligonucleotide probes which contain the
codons for a portion of the determined amino acid
25 sequences can be prepared and used to screen genomic or
cDNA libraries for genes encoding the subject proteins.
The basic strategies for preparing oligonucleotide probes
and DNA libraries, as well as their screening by nucleic
acid hybridization, are well known to those of ordinary
30 skill in the art. See, e.g., *DNA Cloning: Vol. I, supra*;
Nucleic Acid Hybridization, supra; *Oligonucleotide
Synthesis, supra*; Sambrook et al., *supra*. Once a clone
from the screened library has been identified by positive
hybridization, it can be confirmed by restriction enzyme
35 analysis and DNA sequencing that the particular library

00009061-11098

Alternatively, DNA sequences can be prepared synthetically rather than cloned. The DNA sequences can be designed with the appropriate codons for the particular amino acid sequence if the sequences are to be used in protein production. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) *Nature* 292:756; Nambair et al. (1984) *Science* 223:1299; Jay et al. (1984) *J. Biol. Chem.* 259:6311.

25 Once coding sequences for the desired proteins
have been prepared or isolated, they can be cloned into
any suitable vector or replicon. Numerous cloning
vectors are known to those of skill in the art, and the
selection of an appropriate cloning vector is a matter of
30 choice. Examples of recombinant DNA vectors for cloning
and host cells which they can transform include the
bacteriophage λ (*E. coli*), pBR322 (*E. coli*), pACYC177 (*E.*
coli), pKT230 (gram-negative bacteria), pGV1106
(gram-negative bacteria), pLAFR1 (gram-negative
35 bacteria), pME290 (non-*E. coli* gram-negative bacteria),

10

15

20

30

35

produced by culturing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. The protein is then isolated from the host cells and purified. If the expression system secretes the protein into the growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.

The proteins of the present invention may also be produced by chemical synthesis such as solid phase peptide synthesis, using known amino acid sequences or amino acid sequences derived from the DNA sequence of the genes of interest. Such methods are known to those skilled in the art. See, e.g., J. M. Stewart and J. D. Young, *Solid Phase Peptide Synthesis*, 2nd Ed., Pierce Chemical Co., Rockford, IL (1984) and G. Barany and R. B. Merrifield, *The Peptides: Analysis, Synthesis, Biology*, editors E. Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp. 3-254, for solid phase peptide synthesis techniques; and M. Bodansky, *Principles of Peptide Synthesis*, Springer-Verlag, Berlin (1984) and E. Gross and J. Meienhofer, Eds., *The Peptides: Analysis, Synthesis, Biology, supra*, Vol. 1, for classical solution synthesis. Chemical synthesis of peptides may be preferable if a small fragment of the antigen in question is capable of raising an immunological response in the subject of interest.

Analysis of the genome shows the presence of at least six open reading frames, at least one of which encodes the putative DNA replicase gene.

B.3. Preparation of Antigenic Polypeptides and
Conjugation with Carrier

The antigenic region of peptides is generally relatively small--typically 10 amino acids or less in length. Fragments of as few as 5 amino acids may typically characterize an antigenic region. Accordingly, using the genome of PCVII as a basis, DNAs encoding short segments of polypeptides, derived from any of the various ORFs of PCVII, such as ORFs 1-6, and particularly ORF 6, can be expressed recombinantly either as fusion proteins or as isolated peptides. In addition, short amino acid sequences can be chemically synthesized. In instances wherein the synthesized peptide is correctly configured so as to provide the correct epitope, but too small to be immunogenic, the peptide may be linked to a suitable carrier.

A number of techniques for obtaining such linkage are known in the art, including the formation of disulfide linkages using N-succinimidyl-3-(2-pyridylthio)propionate (SPDP) and succinimidyl 4-(N-maleimido-methyl) cyclohexane-1-carboxylate (SMCC) obtained from Pierce Company, Rockford, Illinois. (If the peptide lacks a sulfhydryl, this can be provided by addition of a cysteine residue.) These reagents create a disulfide linkage between themselves and peptide cysteine residues on one protein and an amide linkage through the ϵ -amino on a lysine, or other free amino group in the other. A variety of such disulfide/amide-forming agents are known. See, for example, *Immun. Rev.* (1982) 62:185. Other bifunctional coupling agents form a thioether rather than a disulfide linkage. Many of these thioether-forming agents are commercially available and include reactive esters of 6-maleimidocaproic acid, 2-bromoacetic acid, 2-iodoacetic acid, 4-(N-maleimido-methyl) cyclohexane-1-carboxylic acid, and the like. The

Any carrier may be used, which does not itself induce the production of antibodies harmful to the host, such as the various serum albumins, tetanus toxoids, or keyhole limpet hemocyanin (KLH).

The conjugates, when injected into suitable subjects, will result in the production of antisera which contain immunoglobulins specifically reactive against not only the conjugates, but also against fusion proteins carrying the analogous portions of the sequence, and against appropriate determinants within whole PCVII.

Proteins encoded by the novel viruses of the present invention, or their fragments, can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an antigen of the present invention, or its fragment, or a mutated antigen. Serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) *J. Chrom.* 348:363-370. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.

Monoclonal antibodies to the proteins and to the fragments thereof, can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B

lymphocytes with oncogenic DNA, or transfection with
Epstein-Barr virus. See, e.g., M. Schreier et al.,
Hybridoma Techniques (1980); Hammerling et al.,
Monoclonal Antibodies and T-cell Hybridomas (1981);
5 Kennett et al., *Monoclonal Antibodies* (1980); see also
U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783;
4,444,887; 4,452,570; 4,466,917; 4,472,500, 4,491,632;
and 4,493,890. Panels of monoclonal antibodies produced
10 against the desired protein, or fragment thereof, can be
screened for various properties; i.e., for isotype,
epitope, affinity, etc. Monoclonal antibodies are useful
in purification, using immunoaffinity techniques, of the
individual antigens which they are directed against.
Both polyclonal and monoclonal antibodies can also be
15 used for passive immunization or can be combined with
subunit vaccine preparations to enhance the immune
response. Polyclonal and monoclonal antibodies are also
useful for diagnostic purposes.

20 B.5. Vaccine Formulations and Administration

The novel viral proteins of the present
invention can be formulated into vaccine compositions,
either alone or in combination with other antigens, for
use in immunizing subjects as described below. Methods
25 of preparing such formulations are described in, e.g.,
Remington's Pharmaceutical Sciences, Mack Publishing
Company, Easton, Pennsylvania, 18 Edition, 1990.
Typically, the vaccines of the present invention are
prepared as injectables, either as liquid solutions or
30 suspensions. Solid forms suitable for solution in or
suspension in liquid vehicles prior to injection may also
be prepared. The preparation may also be emulsified or
the active ingredient encapsulated in liposome vehicles.
The active immunogenic ingredient is generally mixed with
35 a compatible pharmaceutical vehicle, such as, for

0609961-11090

Adjuvants which enhance the effectiveness of the vaccine may also be added to the formulation. Such adjuvants include, without limitation, adjuvants formed from aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; oil-in-water and water-in-oil emulsion formulations, such as Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), avridine and dimethyldioctadecyl ammonium bromide (DDA); adjuvants formed from bacterial cell wall components such as adjuvants including monophosphoryl lipid A (MPL) (Imoto et al. (1985) *Tet. Lett.* 26:1545-1548), trehalose dimycolate (TDM), and cell wall skeleton (CWS); adjuvants derived from ADP-ribosylating bacterial toxins, such as derived from diphtheria toxin (for example, CRM₁₉₇, a non-toxic diphtheria toxin mutant (see, e.g., Bixler et al. (1989) *Adv. Exp. Med. Biol.* 251:175; and Constantino et al. (1992) *Vaccine*), pertussis toxin (PT), cholera toxin (CT), the *E. coli* heat-labile toxins (LT1 and LT2), *Pseudomonas* endotoxin A, *C. botulinum* C2 and C3 toxins, as well as toxins from *C. perfringens*, *C. spiriforma* and *C. difficile*; saponin adjuvants such as Quil A (U.S. Pat. No. 5,057,540), or particles generated from saponins such as ISCOMs (immunostimulating complexes); cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; muramyl peptides such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-

isoglutaminy^L-alanine-2- (1'-2'-dipalmitoyl-*sn*-glycero-
3 huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.;
adjuvants derived from the CpG family of molecules, CpG
dinucleotides and synthetic oligonucleotides which
5 comprise CpG motifs (see, e.g., Krieg et al. *Nature*
(1995) 374:546 and Davis et al. *J. Immunol.* (1998)
160:870-876); and synthetic adjuvants such as PCPP
(Poly[di(carboxylatophenoxy)phosphazene] (Payne et al.
Vaccines (1998) 16:92-98). Such adjuvants are
10 commercially available from a number of distributors such
as Accurate Chemicals; Ribi Immunechemicals, Hamilton,
MT; GIBCO; Sigma, St. Louis, MO.

As explained above, the proteins may be linked
to a carrier in order to increase the immunogenicity
15 thereof. Suitable carriers include large, slowly
metabolized macromolecules such as proteins, including
serum albumins, keyhole limpet hemocyanin, immunoglobulin
molecules, thyroglobulin, ovalbumin, and other proteins
well known to those skilled in the art; polysaccharides,
20 such as sepharose, agarose, cellulose, cellulose beads
and the like; polymeric amino acids such as polyglutamic
acid, polylysine, and the like; amino acid copolymers;
and inactive virus particles.

The proteins may be used in their native form
25 or their functional group content may be modified by, for
example, succinylation of lysine residues or reaction
with Cys-thiolactone. A sulfhydryl group may also be
incorporated into the carrier (or antigen) by, for
example, reaction of amino functions with 2-iminothiolane
30 or the N-hydroxysuccinimide ester of 3-(4-dithiopyridyl
propionate. Suitable carriers may also be modified to
incorporate spacer arms (such as hexamethylene diamine or
other bifunctional molecules of similar size) for attach-
ment of peptides.

Other suitable carriers for the proteins of the present invention include VP6 polypeptides of rotaviruses, or functional fragments thereof, as disclosed in U.S. Patent No. 5,071,651, incorporated
5 herein by reference. Also useful is a fusion product of a viral protein and the subject immunogens made by methods disclosed in U.S. Patent No. 4,722,840. Still other suitable carriers include cells, such as lymphocytes, since presentation in this form mimics the
10 natural mode of presentation in the subject, which gives rise to the immunized state. Alternatively, the proteins of the present invention may be coupled to erythrocytes, preferably the subject's own erythrocytes. Methods of coupling peptides to proteins or cells are known to those
15 of skill in the art.

Furthermore, the proteins may be formulated into vaccine compositions in either neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of
20 the active polypeptides) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from free carboxyl groups may also be derived from
25 inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

Vaccine formulations will contain a
30 "therapeutically effective amount" of the active ingredient, that is, an amount capable of eliciting an immune response in a subject to which the composition is administered. Such a response will be demonstrated by either a reduction or lack of symptoms normally displayed
35 by an infected host and/or a quicker recovery time.

The exact amount is readily determined by one skilled in the art using standard tests. The protein concentration will typically range from about 1% to about 95% (w/w) of the composition, or even higher or lower if appropriate.

To immunize a subject, the vaccine is generally administered parenterally, usually by intramuscular injection. Other modes of administration, however, such as subcutaneous, intraperitoneal and intravenous injection, are also acceptable. The quantity to be administered depends on the animal to be treated, the capacity of the animal's immune system to synthesize antibodies, and the degree of protection desired. Effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. The subject is immunized by administration of the vaccine in at least one dose, and preferably two doses. Moreover, the animal may be administered as many doses as is required to maintain a state of immunity to infection.

Additional vaccine formulations which are suitable for other modes of administration include suppositories and, in some cases, aerosol, intranasal, oral formulations, and sustained release formulations. For suppositories, the vehicle composition will include traditional binders and carriers, such as, polyalkaline glycols, or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%. Oral vehicles include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium, stearate, sodium saccharin cellulose, magnesium carbonate, and the like. These oral vaccine compositions may be taken in the form of solutions,

Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function. Diluents such as water, aqueous saline or other known substances can be employed with the subject invention. The nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.

The proteins of the instant invention can also be administered via a carrier virus which expresses the same. Carrier viruses which will find use with the instant invention include but are not limited to the vaccinia and other pox viruses, adenovirus, and herpes virus. By way of example, vaccinia virus recombinants expressing the novel proteins can be constructed as follows. The DNA encoding the particular protein is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which

An alternative route of administration involves gene therapy or nucleic acid immunization. Thus, nucleotide sequences (and accompanying regulatory elements) encoding the subject proteins can be administered directly to a subject for *in vivo* translation thereof. Alternatively, gene transfer can be accomplished by transfecting the subject's cells or tissues *ex vivo* and reintroducing the transformed material into the host. DNA can be directly introduced into the host organism, i.e., by injection (see U.S. Patent Nos. 5,580,859 and 5,589,466; International Publication No. WO/90/11092; and Wolff et al. (1990) *Science* 247:1465-1468). Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., U.S. Patent No. 5,703,055; Hazinski et al. (1991) *Am. J. Respir. Cell Mol. Biol.* 4:206-209; Brigham et al. (1989) *Am. J. Med. Sci.* 298:278-281; Canonico et al. (1991) *Clin. Res.* 39:219A; and Nabel et al. (1990) *Science* 249:1285-1288. Targeting agents, such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid can be delivered to specific tissues and cells susceptible to infection.

As explained above, the proteins of the present invention may also be used as diagnostics to detect the presence of reactive antibodies of PCVII in a biological

sample in order to determine the presence of PCVII infection. For example, the presence of antibodies reactive with the proteins can be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays. Such assays include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, etc. The reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.

The aforementioned assays generally involve separation of unbound antibody in a liquid phase from a solid phase support to which antigen-antibody complexes are bound. Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidene fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.

Typically, a solid support is first reacted with a solid phase component (e.g., one or more PCVII proteins) under suitable binding conditions such that the component is sufficiently immobilized to the support. Sometimes, immobilization of the antigen to the support can be enhanced by first coupling the antigen to a protein with better binding properties. Suitable coupling proteins include, but are not limited to, macromolecules such as serum albumins including bovine

serum albumin (BSA), keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art. Other molecules that can be used to bind the antigens to the support include polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and the like. Such molecules and methods of coupling these molecules to the antigens, are well known to those of ordinary skill in the art. See, e.g., Brinkley, M.A. *Bioconjugate Chem.* (1992) 3:2-13; Hashida et al., *J. Appl. Biochem.* (1984) 6:56-63; and Anjaneyulu and Staros, *International J. of Peptide and Protein Res.* (1987) 30:117-124.

After reacting the solid support with the solid phase component, any non-immobilized solid-phase components are removed from the support by washing, and the support-bound component is then contacted with a biological sample suspected of containing ligand moieties (e.g., antibodies toward the immobilized antigens) under suitable binding conditions. After washing to remove any non-bound ligand, a secondary binder moiety is added under suitable binding conditions, wherein the secondary binder is capable of associating selectively with the bound ligand. The presence of the secondary binder can then be detected using techniques well known in the art.

More particularly, an ELISA method can be used, wherein the wells of a microtiter plate are coated with a desired protein. A biological sample containing or suspected of containing anti-protein immunoglobulin molecules is then added to the coated wells. After a period of incubation sufficient to allow antibody binding to the immobilized antigen, the plate(s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule added. The secondary binding molecule is allowed to react with any captured sample

Thus, in one particular embodiment, the presence of bound anti-antigen ligands from a biological sample can be readily detected using a secondary binder comprising an antibody directed against the antibody ligands. A number of anti-porcine immunoglobulin (Ig) molecules are known in the art which can be readily conjugated to a detectable enzyme label, such as horseradish peroxidase, alkaline phosphatase or urease, using methods known to those of skill in the art. An appropriate enzyme substrate is then used to generate a detectable signal. In other related embodiments, competitive-type ELISA techniques can be practiced using methods known to those skilled in the art.

Assays can also be conducted in solution, such that the proteins and antibodies specific for those proteins form complexes under precipitating conditions. In one particular embodiment, proteins can be attached to a solid phase particle (e.g., an agarose bead or the like) using coupling techniques known in the art, such as by direct chemical or indirect coupling. The antigen-coated particle is then contacted under suitable binding conditions with a biological sample suspected of containing antibodies for the proteins. Cross-linking between bound antibodies causes the formation of particle-antigen-antibody complex aggregates which can be precipitated and separated from the sample using washing and/or centrifugation. The reaction mixture can be analyzed to determine the presence or absence of antibody-antigen complexes using any of a number of standard methods, such as those immunodiagnostic methods described above.

In yet a further embodiment, an immunoaffinity matrix can be provided, wherein a polyclonal population of antibodies from a biological sample suspected of containing antibodies to the protein of interest is
5 immobilized to a substrate. In this regard, an initial affinity purification of the sample can be carried out using immobilized antigens. The resultant sample preparation will thus only contain anti-PCVII moieties, avoiding potential nonspecific binding properties in the
10 affinity support. A number of methods of immobilizing immunoglobulins (either intact or in specific fragments) at high yield and good retention of antigen binding activity are known in the art. Not being limited by any particular method, immobilized protein A or protein G can
15 be used to immobilize immunoglobulins.

Accordingly, once the immunoglobulin molecules have been immobilized to provide an immunoaffinity matrix, labeled proteins are contacted with the bound antibodies under suitable binding conditions. After any
20 non-specifically bound antigen has been washed from the immunoaffinity support, the presence of bound antigen can be determined by assaying for label using methods known in the art.

Additionally, antibodies raised to the
25 proteins, rather than the proteins themselves, can be used in the above-described assays in order to detect the presence of antibodies to the proteins in a given sample. These assays are performed essentially as described above and are well known to those of skill in the art.

Furthermore, nucleic acid-based assays may also
30 be conducted. In this regard, using the disclosed PCVII nucleic acid sequences as a basis, oligomers can be prepared which are useful as hybridization probes or PCR primers to detect the presence of the viral genome in,
35 for example, biological samples from subjects suspected

The oligomers may be used as probes in diagnostic assays. In a representative assay, the biological sample to be analyzed is treated to extract the nucleic acids contained therein. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques. Alternatively, the nucleic acid sample may be dot-blotted without size separation. The probes are then labeled with a reporter moiety. Suitable labels, and methods for labeling probes, are known in the art and include, for example, radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent probes and chemiluminescent probes. The nucleic acids extracted from the sample are then treated with the labeled probe under hybridization conditions of suitable stringencies.

The probes can be made completely complementary to the targeted PCVII gene sequence. However, when longer probes are used in the diagnostic assays, the amount of complementarity may be less. Generally, conditions of high stringency are used in the assay methods, especially if the probes are completely or highly complementary. However, lower stringency

In a more specific embodiment, the above-described method includes the use of PCVII nucleic acid specific probes where two probes (primers) define an internal region of the PCVII genome. In this embodiment, each probe has one strand containing a 3'-end internal to the PCVII nucleic acid internal region. The nucleic acid/probe hybridization complexes are then converted to double-strand probe containing fragments by primer extension reactions. Probe-containing fragments are amplified by successively repeating the steps of (i) denaturing the double-stranded fragments to produce single-stranded fragments, (ii) hybridizing the single strands with the probes to form strand/probe complexes, (iii) generating double-stranded fragments from the strand/probe complexes in the presence of DNA polymerase and all four deoxyribonucleotides, and (iv) repeating steps (i) to (iii) until a desired degree of amplification has been achieved. Amplification products are then identified according to established procedures. The method of the invention may further include a third polynucleotide probe capable of selectively hybridizing to the internal region described above but not to the specific probe/primer sequences used for amplification.

PCR techniques, such as those described above, are well known in the art. See, e.g., *PCR Protocols: A Guide to Methods and Applications* (Academic Press); *PCR A Practical Approach* (IRL press); Saiki et al. (1986) *Nature* 324:163.

Other assays for use herein include the

10 Additionally, EP 124221 describes a DNA hybridization assay wherein the analyte is annealed to a single-stranded DNA probe that is complementary to an enzyme-labelled oligonucleotide, and the resulting tailed duplex is hybridized to an enzyme-labelled
15 oligonucleotide. EP 204510 describes a DNA hybridization assay in which analyte DNA is contacted with a probe that has a tail, such as a poly-dT-tail, an amplifier strand that has a sequence that hybridizes to the tail of the probe, such as a poly-A sequence, and which is capable of
20 binding a plurality of labelled strands. The technique first may involve amplification of the target PCVII sequences in sera to approximately 10^6 sequences/ml, as described above. The amplified sequence(s) then may be detected using a hybridization assay known in the art.

The above-described assay reagents, including the proteins, antibodies thereto or oligomers, can be

provided in kits, with suitable instructions and other necessary reagents, in order to conduct immunoassays as described above. The kit can also contain, depending on the particular immunoassay used, suitable labels and
5 other packaged reagents and materials (i.e. wash buffers and the like). Standard immunoassays, such as those described above, can be conducted using these kits.

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not
10 intended to limit the scope of the present invention in any way.

C. Experimental

15

Materials and Methods

Cell cultures. The Dulac cell line, a PCV-free PK15 derivative, was obtained from Dr. John Ellis
20 (University of Saskatchewan, Saskatoon, Saskatchewan). The Vero cell line was obtained from American Type Culture Collection (ATCC), Manassas, VA. These cells were cultured in media suggested by the ATCC and incubated at 37°C with 5% CO₂.

Porcine circoviruses. The classic PCVI was isolated from persistently infected PK15 cells (ATCC CCL33). Isolate PCVII 412 was obtained from lymph nodes of a piglet challenged with the lymph node homogenate from PMWS-affected piglets. This challenged piglet had
25 been diagnosed with PMWS. Isolate PCVII 9741 was isolated from the buffy-coat of peripheral blood from a PMWS-affected piglet of the same herd after the isolation of PCVII 412. Isolate PCVII B9 was isolated from an affected piglet in a United States swine herd with a PMWS
30 clinical outbreak in the fall of 1997.

Propagation of PCVI. PCVI from persistently infected PK15 cells was grown and purified using a modified method of Tischer et al (1987) *Arch. Virol.* 96:39-57. Briefly, PCV harvested from PK15 cells was used to super-infect a monolayer of PK15 cells at about 1 moi for two hours before the cells were treated with 300 mM D-glucosamine. After washing the cells once, DMEM (Gibco, catalog number 21013) with 5% FBS was added to the cells and the cells were incubated for an additional four days. The infected cells were scraped off and collected after centrifugation at 1500 x g for 15 minutes. The cell pellet was then treated with 0.5% of Triton X-114 at 37°C for 30 minutes. After another low speed centrifugation to remove cellular debris, an equal amount of Freon (Sigma catalog number T-5271) was added to the supernatant and the mixture was homogenized for one minute using a Polytron at maximum speed. The mixture was then centrifuged and the top layer collected and mixed with an equal volume of 0.1 M PBS. The virus pellet was collected after ultra centrifugation into a 20% sucrose cushion at 210,000 x g for 30 minutes.

Culture of the field isolates (PCVII). The isolate PCVII 412 was cultured and purified in a similar manner as PCVI, except Dulac cells were used. The isolate PCVII B9 was grown in heterogenic Vero cells transfected with self-ligated full-length PCR products from the United States PMWS outbreak. Therefore, the possibility of contamination from other pig pathogens was eliminated. The B9-transfected Vero cells were continuously passed and treated with 300 mM D-glucosamine as described above.

Viral DNA isolation. Viral DNA was extracted from variable sources, including pellets of infected Dulac and Vero cells, peripheral blood buffy-coat cells,

tissues from infected animals and serum. The tissue samples were treated with proteinase K and viral DNA was extracted using either phenol/chloroform or Qiagen tissue kit (Qiagen, Santa Clarita, CA). DNA from peripheral
5 blood buffy coat cells of heparinized blood and serum was similarly collected using the Qiagen blood kit.

Infection of piglets. Piglets were derived from specific pathogen-free sows. At one day of age, each piglet received approximately one gram of lymph
10 nodes collected from PMWS-affected piglets. The tissue homogenate was distributed equally between the oral and intraperitoneal routes. Ten piglets were used in each of the experimental groups and observed daily for 7 weeks. Two groups were challenged and 2 were uninfected
15 controls. Two groups, one challenged and one control, were also treated with cyclosporin A (2mg/kg) at Day 0 and Day 14. The piglets were fed canned milk (Carnation) and water (50:50) until they self-weaned to high nutrient density commercially prepared feed.

PCR, cloning and sequencing of the field PCV Isolates. A two-step approach was used for the initial
20 cloning of isolate PCVII 412 viral genomic DNA. A primer that hybridized to the conserved loop stem sequences, Loop⁻ (Table 1), was designed to perform a single-primed
25 PCR taking advantage of the complementary sequences and the circular nature of PCV genomic DNA. The PCR reaction for the single-primed PCR was a two-stage process. The first stage consisted of 5 cycles of denaturing at 94°C for 1 minute, annealing at 37°C for 30 seconds and
30 extension at 72°C for 2 minutes. The second stage consisted of 25 cycles of a similar program except the annealing temperature was increased to 52°C. The PCR products were cloned into a TA cloning vector
(Invitrogen, Carlsbad, CA). Both strands of three
35 different clones were sequenced to ensure sequence

SECRET-109

fidelity. Based on the sequences obtained, primer 1000- and R1F were designed in the noncoding region of the viral DNA sequences and used to clone the full-length viral genome. The sequences of all the primers used in this study are shown in Table 1. The sequences of the loop region were then obtained from the full-length clone. Sequences of isolate PCVII 9741 and PCVII B9 were obtained from purified PCR products. Automated DNA sequencing performed by Plant Biotechnology Institute of NRC, Canada was used with several internal primers. The sequences of isolates PCVII 412 (AF085695), PCVII 9741 (AF086835) and PCVII B9 (AF086834) have been deposited with the National Center for Biotechnology Information (NCBI).

Table 1
The Sequences of Primers Used in the Studies

Primer Name	Primer Sequence	SEQ ID NO:
Loop	ACTACAGCAGCGCACTTC	13
1000-	AAAAAAGACTCAGTAATTTATTTTCATATGG	14
R1F	ATCACTTCGTAATGGTTTTTATT	15
1710+	TGCGGTAACGCCTCCTTG	16
850-	CTACAGCTGGGACAGCAGTTG	17
1100+	CATACATGGTTACACGGATATTG	18
1570-	CCGCACCTTCGGATATACTG	19
1230-	TCCCGTTACTTCACACCCAA	22
400+	CCTGTCTACTGCTGTGAGTA	23

Sequence analyses. The sequences of other circoviruses were obtained from NCBI. Various public domains were used for the sequence analysis, such as Biology workbench, Blast search, DNA/protein analysis

tools, etc. The sequence alignments were generated using Clustal W program (Biology Workbench, internet address: <http://biology.ncsa.uiuc.edu>) and phylogenetic trees were created by PAUP 3.1 program (David L. Swofford, Laboratory of Molecular Systematics, MRC534, MRC at Smithsonian Institution, Washington, D.C.).

Multiplex PCR. Two sets of primers were designed to identify the PCV group-specific sequences and strain-specific sequences. The primer pair 1710+/850- is PCV-group specific and 1100+/1570- is the novel PCV strain-specific pair, which differentiates the novel PCV from the one derived from PK15 cells. The two sets of primers have similar annealing temperatures for the PCR reaction and were used together at 0.5 μ M concentration in a standard hot start PCR reaction. Either Ampli Taq Gold (Perkin Elmer) or Plentinum Taq (Gibco) was used.

Antiserum. The standard Berlin rabbit anti-PCVI antibody was kindly provided by Dr. Tischer (Koch Institute, Berlin, FRG). Rabbit anti-PCVII 412 pooled serum was obtained from two rabbits injected with purified isolate PCVII 412 at 50 μ g/dose in an oil-in-water emulsion. The injection was repeated 3 times at 21-day intervals. Pig anti-PMWS serum was collected from convalescent pigs from PMWS affected herds.

ELISA. Purified PCV was diluted in sodium carbonate buffer (0.05 M) pH 9.6 to a concentration of 0.5 μ g per 100 μ l and used to coat Immulon II plates (Dynatech Laboratories, Inc.). The plates were washed six times with TTBS (20mM Tris-HCl, 500 mM NaCl, 0.05% of Tween 20, pH 7.5) before serially diluted primary rabbit or pig antibody was added. After six washes with TTBS, alkaline phosphatase-conjugated secondary antibodies (1/5000 dilution), either anti-rabbit or anti-pig (Kirkegaard & Perry), were added. Plates were developed with 100 μ l/well of p-Nitrophenyl Phosphate (PNPP, 3g/L)

in 1 M diethanolamine, 0.5 MgCl_2 , pH 9.8 and the plates were read on an ELISA reader (BioRad) at 405/490 nm.

FACS analysis of lymphocyte surface markers.

Blood samples were collected from PMWS affected
5 piglets in the field and negative control. The RBC was lysed and WBC was stained with anti-pig CD3, CD4 and CD8 monoclonal antibodies, and followed by fluorescence labeled anti-mouse secondary antibody. The specifically labeled cells were fixed with 2% formaldehyde and 5000
10 cells were counted using FACS system (Becton Dickinson).

Example 1

PMWS Reproduction

PMWS has not been reproduced under controlled
15 conditions, nor have etiology studies been performed. In order to determine the causative agent of this disease, a number of tissues were collected from PMWS-affected pigs, as described above in Materials and Methods, and studied. Lymph nodes displayed the most apparent gross lesions,
20 histopathological changes and circovirus infection was confirmed by immunostaining. Accordingly, the lymph nodes were used in the challenge experiments described above.

The challenge experiments, conducted as
25 described in Materials and Methods were successful in producing PMWS in pigs. In particular, some piglets died of the infection and asymptotically infected piglets developed PMWS-like microscopic lesions by the end of the trial.

30 In another challenge experiment, the starting material used was lung tissue of pig with chronic wasting and lymph node enlargement. These clinical signs are characteristic of PMWS. The tissue was combined with sterile 0.1 M phosphate-buffered saline (PBS) and
35 homogenized by passage through a polytron mixer. The

0000961-1109
SECRET

Blood samples were obtained throughout the experiment and tissue samples were taken postmortem. The samples were tested for PCVII viral DNA by PCR, using PCR primers 1230- and 400+ (Table 1) which resulted in an 830 base pair product. Four of the pigs given the lung tissue extract had positive blood samples; whereas none of the pigs given placebo had PCVII DNA detected in their blood. PCVII was detected in one or more tissues from 7 of the 8 surviving pigs in the "virus challenge" treatment group whereas all tissues from pigs in the control group were negative for PCVII. Contingency table analysis showed a significant difference ($p < 0.001$; two-tailed Fishers exact-test).

A total of 20 weaned piglets (approximately three weeks of age) were randomly (balanced by litter of birth, gender and body weight) assigned to "control" or "virus challenge" treatment groups. Pigs were weaned on Day 0 at approximately three weeks of age. In general, clinical signs of PMWS disease included enlarged lymph nodes and wasting or poor growth. Enlarged lymph nodes were detected in significantly ($p < 0.02$; two-tailed Fisher exact-test) more pigs in the group treated with virus (7 pigs) than in the group treated with placebo (1 pig). The average daily gain in the group treated by virus injection (580 gm/d) tended to be less than the group given the placebo (616 gm/d), but the difference was not significant ($p = 0.17$; two-tailed paired t-Test). There was no difference between groups in the relative mass of internal organs (liver, lung, heart, spleen, kidneys).

All blood samples, including those taken just prior to euthanasia were negative for PCVII. PCVII was detected in one or more tissues for 8 of the 10 pigs in the "virus challenge" treatment group whereas all tested tissues from pigs in the control group were negative for

PCVII. Contingency table analysis showed that this was a significant difference ($p < 0.001$; two-tailed Fishers exact-test).

In conclusion, these experiments confirm that
5 injection of weaned piglets with tissue extracts and
gradient-purified viral material containing PCVII results
in infection of multiple tissues. The infection persists
for a duration of at least eight weeks.

10

Example 2

Isolation and propagation of PCVII

To determine the presence of an infectious
causative agent(s) for PMWS, various tissues from pig
#412, an experimentally challenged piglet sacrificed 21
15 days post-infection, were used for viral isolation.
After continued passage of lymph node samples from pig
#412 in Dulac cells, virus accumulation or adaptation was
observed. A unique pattern of cytopathic effect
initially developed, followed by increasing virus titer,
20 as determined by ELISA using the standard Berlin anti-PCV
antibody, as described above.

The existence of circovirus in Dulac cells
infected with isolate PCVII 412 was then detected by
electron microscopic examination. After six passages,
25 viral structure proteins could be detected consistently,
using a western blot assay.

Example 3

Specific anti-PCVII antibodies in
30 asymptomatically infected and convalescent
piglets in PMWS-affected herds

Because it appeared that porcine circoviruses
possessed some heterogeneity, ELISAs were performed using
sera of piglets, collected from a herd with a PMWS
35 outbreak, against the PCV and isolate PCVII 412 virus.

2025 RELEASE UNDER E.O. 14176

Example 4

10

15

35

of PCVII 412 with PCVI and Figures 4A-4B for comparisons of the PCVII 412 sequence with the various PCV isolates.

The results of a phylogenetic analysis using the PAUP 3.1 program suggested that the new PMWS isolates were closely related and in a different cluster with PCVI. These isolates were therefore termed "PCVII" isolates. The percent nucleotide sequence homologies among isolates of the novel porcine circovirus were more than 99% identical. In contrast, comparison of these nucleotide sequences with the PK15 PCVI showed only 75.8% overall nucleotide sequence homology. Comparative analysis of nucleotide sequences in different regions further revealed that the putative replication-associated protein gene of these two viruses share 81.4% homology, while the nucleotide sequences of the other large ORF was only 67.6% homologous.

Furthermore, nucleotide insertions and deletions (indels) were found in three regions. There are 13 base insertions in the new isolates between PCVI sequence 38-61 that flank the start codon for the putative 35.8 kd protein encoded by ORF 1. The area of PCVI 915-1033, containing 15 base indels, was at the ends and the joint region of the two largest ORFs (the other ORF was antisense) of the porcine circoviruses. The third region, covering PCVI sequence from 1529-1735 with 15 base indels, locates at the amino end of a putative 27.8 kd protein encoded by ORF 6. PCVI sequences were also compared with the available sequences of the rest of the members of Circoviridae. PCVI is more closely related to banana bunch top virus (BBTV), a plant virus, than to chicken anemia virus (CAV) and beak and feather disease virus (BFDV) (both of which are avian circoviruses).

The gene map of isolate PCVII 412 is shown in Figure 1. There are a total of six potential ORFs

25
30
35

Table 2 Putative Amino Acid Sequence Comparison Between PK15 PCVI and PCVII 412			
Open reading frames		Sequence Homology, %	Predicted Localization and Function
PCVI	412	PCVI/412	
47-983 (ORF 1)	51-992 (ORF 1)	83.5	Nucleus, putative Rep protein
1723-1024 (ORF 6)	1735-1037 (ORF 6)	66.4	Nucleus
552-207 (ORF 4)	565-389 (ORF 3)	40.9	Endoplasmic Reticulum
658-40 (ORF 3)	671-359 (ORF 2)	29.1	Microbody

Example 5

Purification of PCVII using molecular cloning method

Dulac cells were found to be infected with porcine retrovirus which is also found in many pig origin cell lines. In addition, other porcine pathogens were also found inconsistently associated with PCVII in PMWS-affected piglets. Thus, to obtain pure PCVII cultures, genetically cloned PCVII DNA was transferred to the susceptible non-porcine origin Vero cells using liposomes. After two passages, amplified PCV antigens were detected in the cells. The PCVII was seen to replicate and accumulate in the nuclei and was released into cytoplasm and other cells during cell mitosis.

Example 6

Multiplex PCR in PCVII identification and PMWS diagnosis

In order to differentiate the two strains of porcine circoviruses, PCVI and PCVII, two sets of primers were designed based upon the comparative analysis of the viral DNA sequences. The PCV group-specific pair of 1710+/850, and isolate PCVII 412 strain-specific

1100+/1570⁻, were used in multiplex PCR for testing field samples. These primer sets were used with frozen tissues and buffy coat cells of peripheral blood. As judged by the multiplex PCR, using those primer sets, not only was PCVII infection identified in these samples but the genetic relatedness of the field samples was also determined. The presence of circovirus was later confirmed by electron microscopy.

The potency of this diagnostic method was further tested with another group of samples collected from a PMWS-affected herd (see Figure 5). The PCVII DNA sequences could also be identified in almost all the tissues in PMWS-affected piglets (Figure 6).

Example 7

PCVII viremia prior to and during PMWS outbreak

The development of PCR using serum enabled us to test the PCVII viremia in a swineherd showing specific anti-PCVII antibody. A group of 23 piglets was monitored from the age of one day until seven weeks and samples were collected at approximately two week intervals. A full-course of PCVII viremia and PMWS outbreak were observed, as indicated by the appearance to disappearance of the PCVII viremia which was detected in 9 of the 23 piglets. Most of piglets which showed PCVII viremia developed PMWS with some exhibiting severe PMWS. Table 3 shows the manifestation of PMWS in a typical pig. Gross lesions were found in most organs and tissues (Table 3).

Table 3. A clinical, histology, virology and immunology report of a typical PMWS affected piglet.

	PMWS pig	Gross appearance	Histopath	PCR
5	H254	Spine, hairy, disinterested and wobbled		
	Saliva	ND	ND	ND
	Urine	Pale/clear	ND	+
	Bile	Thin, not viscid	ND	+
	Feces	Scant but normal	ND	+
	Serum	N	ND	+
10	Plasma	Yellow	ND	+
	Skin	Hint of yellow		+
	Fat	Little/no fat		+
	Muscle	N		+
	Tongue	N	Glossitis	+
	Tonsil	Small crypts	Lymphocyte depletion	+
	Cerv. LN	Enlarged	Lymphocyte depletion	+
15	Med. LN	Very large, dark surface, yellow center	Lymphocyte depletion	+
	Mesenteric LN	Very enlarged, dark and wet	Lymphocyte depletion	+
	Inguinal LN	Large, dark and wet	Lymphocyte depletion	+
	Spleen	Small and thin	Lymphocyte depletion	+
	Thymus	Small and difficult to find	ND	+
	Treachea	N	Metaplasia adenitis	+
	Lung	A, M lobes 80% atelectasis; firm texture	Interstitial	
20		mottles and spots throughout all lobes	Pneumonia	+
	Heart	Thin and flabby		+
	Liver	"Camouflage" pattern mottling		+
	Gall Bladder	N, moderately full		+
	Pancreas	N		+
	Adrenal	N	Focal adrenalitis	+
	Brain	N	Meningitis	+
25	Eye	N, white sclera		+
	Stomach	N, full of feed		+
	Small intestine	N	Peyers Patch	+
	Large intestine	N, sandy/gritty contents	Submucosal inflam	+
	Kidney	Enlarged, dark and no pus	Interstitial nephritis	+
	Urinary bladder	N		+
			Ref mg x 10 ⁹ /L	
	CBC	WBC: 20.1	11.0-22.0	
30		Segs: 62% or 12.462	3.08-10.4	
		Lymphs: 29.0% or 5.829	4.29-13.6	
	FACS	CD3: 52.1%	55%	
		CD4: 9.0%	30%	
		CD8: 66.5%	15%	
35				

09209964-11098

Example 8

Host immune system dysfunction in PMWS affected piglets

It is interesting that while lymphocyte infiltration was discovered in most of the tissues, lymphocyte depletion was consistently found in all the lymphoid tissues (Table 3). Decreased CD4 cell, and increased CD8 cells were also seen, while CD3 cells remained relatively stable (Table 4, mean numbers are from two PMWS affected and 40 negative control piglets). These changes resulted in CD4/CD8 ratio which drastically dropped from 1.58 to 0.13. These finding suggested that PCVII could induce host immune system malfunction and therefore suppress the host immune responses to PCVII and possibly other pathogens. Thus, PMWS appears to be a disease of immunodeficiency in piglets.

Table 4 Lymphocyte Surface Markers of PMWS Affected and Control of 6-week-old Piglets				
	CD3	CD4	CD8	CD4/CD8 Ratio
PMWS	59.88	8.85	67.6	0.13
Control	53.46	24.02	15.18	1.58

Deposits of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of clone B9WTA, a clone including the full-length nucleic acid sequence of PCVII B9 as depicted in Figures 4A-4B, was made with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA on _____ and assigned Accession No. _____. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. The deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and

the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures for a period of thirty (30) years from the date of deposit. The organisms will be made available by the ATCC under the
5 terms of the Budapest Treaty, which assures permanent and unrestricted availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. §122 and the Commissioner's rules pursuant thereto
10 (including 37 C.F.R. §1.12 with particular reference to 886 OG 638). Upon the granting of a patent, all restrictions on the availability to the public of the deposited cultures will be irrevocably removed.

These deposits are provided merely as
15 convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. §112. The nucleic acid sequences of these genes, as well as the amino acid sequences of the molecules encoded thereby, are incorporated herein by reference and are
20 controlling in the event of any conflict with the description herein.

Thus, the cloning, expression and
characterization of novel PCVII isolates is disclosed, as
25 are methods of using the same. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

30

35

Claims

1. An isolated polynucleotide capable of selectively hybridizing to a porcine circovirus Type II (PCVII) nucleotide sequence, wherein the polynucleotide comprises at least about 8 contiguous nucleotides derived from, or complementary to, a PCVII sequence depicted in Figures 4A-4C (SEQ ID NO:1, SEQ ID NO:11 and SEQ ID NO:12).
2. The polynucleotide of claim 1, wherein said polynucleotide is at least 10 nucleotides in length.
3. The polynucleotide of claim 1, wherein said polynucleotide is at least 15 nucleotides in length.
4. The polynucleotide of claim 1, wherein said polynucleotide is at least 20 nucleotides in length.
5. The polynucleotide of claim 1, wherein said polynucleotide comprises a sequence having at least about 85% identity to a PCVII sequence depicted in Figures 4A-4C (SEQ ID NO:1, SEQ ID NO:11 and SEQ ID NO:12), or a fragment thereof comprising at least about 75 contiguous nucleotides.
6. The polynucleotide of claim 5, wherein said polynucleotide comprises a PCVII sequence selected from the group consisting of PCVII 412 (SEQ ID NO:1), PCVII 9741 (SEQ ID NO:11) and PCVII B9 (SEQ ID NO:12).
7. A polynucleotide encoding an immunogenic porcine circovirus Type II (PCVII) polypeptide having at least about 85% identity to a polypeptide selected from the group consisting of a polypeptide derived from (a)

open reading frame (ORF) 1 (SEQ ID NO:3), (b) ORF 2 (SEQ ID NO:9), (c) ORF 3 (SEQ ID NO:7), (d) ORF 4 (SEQ ID NO:20), (e) ORF 5 (SEQ ID NO:21), (f) ORF 6 (SEQ ID NO:5), and (g) immunogenic fragments of (a)-(f) comprising at least about 5 amino acids.

8. The polynucleotide of claim 7, wherein the polynucleotide encodes an immunogenic PCVII polypeptide having at least about 85% identity to a polypeptide derived from ORF 6 (SEQ ID NO:5), or immunogenic fragments thereof comprising at least about 5 amino acids.

9. The polynucleotide of claim 8, wherein the polynucleotide encodes the polypeptide of ORF 6 (SEQ ID NO:5).

10. A recombinant vector comprising:
(a) a polynucleotide according to claim 1; and
(b) control elements that are operably linked to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

11. A recombinant vector comprising:
(a) a polynucleotide according to claim 5; and
(b) control elements that are operably linked to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

12. A recombinant vector comprising:
(a) a polynucleotide according to claim 7; and

(b) control elements that are operably linked to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is
5 heterologous to said coding sequence.

13. A recombinant vector comprising:

(a) a polynucleotide according to claim 8; and

(b) control elements that are operably linked
10 to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

14. A recombinant vector comprising:

(a) a polynucleotide according to claim 9; and

(b) control elements that are operably linked
15 to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is
20 heterologous to said coding sequence.

15. A host cell transformed with the recombinant vector of claim 10.

16. A host cell transformed with the recombinant vector of claim 11.

17. A host cell transformed with the
30 recombinant vector of claim 12.

18. A host cell transformed with the recombinant vector of claim 13.

35

09209931-21093

19. A host cell transformed with the recombinant vector of claim 14.

20. A method of producing a recombinant PCVII polypeptide comprising:

(a) providing a population of host cells according to claim 15; and

(b) culturing said population of cells under conditions whereby the PCVII polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

21. A method of producing a recombinant PCVII polypeptide comprising:

(a) providing a population of host cells according to claim 16; and

(b) culturing said population of cells under conditions whereby the PCVII polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

22. A method of producing a recombinant PCVII polypeptide comprising:

(a) providing a population of host cells according to claim 17; and

(b) culturing said population of cells under conditions whereby the PCVII polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

23. A method of producing a recombinant PCVII polypeptide comprising:

(a) providing a population of host cells according to claim 18; and

(b) culturing said population of cells under conditions whereby the PCVII polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

5

24. A method of producing a recombinant PCVII polypeptide comprising:

(a) providing a population of host cells according to claim 19; and

10

(b) culturing said population of cells under conditions whereby the PCVII polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

15

25. Protein produced by the method of claim

20.

26. Protein produced by the method of claim

21.

20

27. Protein produced by the method of claim

22.

28. Protein produced by the method of claim

25

23.

29. Protein produced by the method of claim

24.

30

30. An immunogenic porcine circovirus Type II (PCVII) polypeptide having at least about 85% identity to a polypeptide selected from the group consisting of a polypeptide derived from (a) open reading frame (ORF) 1 (SEQ ID NO:3), (b) ORF 2 (SEQ ID NO:9), (c) ORF 3 (SEQ ID NO:7), (d) ORF 4 (SEQ ID NO:20), (e) ORF 5 (SEQ ID

35

Patent 960260

NO:21), (f) ORF 6 (SEQ ID NO:5), and (g) immunogenic fragments of (a)-(f) comprising at least about 5 amino acids.

5 31. The polypeptide of claim 30, wherein the polypeptide has at least about 85% identity to a polypeptide derived from ORF 6 (SEQ ID NO:5), or immunogenic fragments thereof comprising at least about 5 amino acids.

10 32. The polypeptide of claim 31, wherein the polypeptide has the sequence of the polypeptide encoded by ORF 6 (SEQ ID NO:5).

15 33. Antibodies raised by the polypeptide of claim 30.

20 34. Antibodies raised by the polypeptide of claim 31.

 35. Antibodies raised by the polypeptide of claim 32.

25 36. A composition comprising an immunogenic PCVII polypeptide according to claim 30 and a pharmaceutically acceptable vehicle.

30 37. A composition comprising an immunogenic PCVII polypeptide according to claim 31 and a pharmaceutically acceptable vehicle.

35 38. A composition comprising an immunogenic PCVII polypeptide according to claim 32 and a pharmaceutically acceptable vehicle.

9000-0040 PATENT

39. The composition of claim 36 further comprising an adjuvant.

40. A method of producing a composition
5 comprising providing an immunogenic PCVII polypeptide according to claim 30 and combining said polypeptide with a pharmaceutically acceptable vehicle.

41. A method of treating or preventing PCVII
10 infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a composition according to claim 30.

42. A method of detecting porcine circovirus
15 Type II (PCVII) antibodies in a biological sample comprising:

(a) providing a biological sample;
(b) reacting said biological sample with an
immunogenic PCVII polypeptide according to claim 30,
20 under conditions which allow PCVII antibodies, when present in the biological sample, to bind to said PCVII polypeptide to form an antibody/antigen complex; and
(c) detecting the presence or absence of said
complex,

25 thereby detecting the presence or absence of PCVII antibodies in said sample.

43. An immunodiagnostic test kit for detecting
PCVII infection in a vertebrate subject, said test kit
30 comprising an immunogenic PCVII polypeptide according to claim 30, and instructions for conducting the immunodiagnostic test.

15

20

30

35

35

POSTWEANING MULTISYSTEMIC WASTING SYNDROME
VIRUS FROM PIGS

Abstract of the Disclosure

5 The cloning of a novel PCVII viral genome is
described as is expression of proteins derived from the
PCVII genome. These proteins can be used in vaccine
compositions for the prevention and treatment of PCVII
infections, as well as in diagnostic methods for
10 determining the presence of PCVII infections in a
vertebrate subject. Polynucleotides derived from the
viral genome can be used as diagnostic primers and
probes.

15

20

25

30

35

960727-13650260




FIG. 1

1	accagcgcacttcggcgagcggcagcacctcggcagcacctcagcagcaacatgccagca	60
1	tggtcgcgtgaagccgtcgcgcgtcgtggagccgtcgtggagtcgtcgttgtagcgggtcgt	
	M P S K	
61	agaagaatggaagaagcggaccccaaccacataaaagggtgggtgttcacgctgaataatc	120
1	tcttcttaccttcttcgcctgggttggtgtatgtttccaccacacaagtgcgacttattag	
	K N G R S G P Q P H K R W V F T L N N P	
121	cttccgaagacgagcgcgaagaaaatacgggagctcccaatctccctatttgattatgtta	180
1	gaaggcttctgctcgcgttcttttatgccctcgaggggttagagggataaactaataaaat	
	S E D E R K K I R E L P I S L F D Y F I	
181	ttgttggcgaggagggtaatgaggaaggacgaacacctcacctccaggggttcgctaatt	240
1	aacaaccgctcctccattactccttcctgcttggtggagtgagggtccccaagcgattaa	
	V G E E G N E E G R T P H L Q G F A N F	
241	ttgtgaagaagcaaacttttaataaaagtgaagtgggtatgttggtgcccgtgccacatcg	300
1	aacacttcttctgtttgaaaattatttcacttcaccataaaccacgggcgacggtgtagc	
	V K K Q T F N K V K W Y L G A R C H I E	
301	agaaagccaaaggaactgatcagcagaataaagaatattgtagtaaagaaggcaacttac	360
1	tctttcgggttctccttgactagtcgtcttatttcttataacatcatttcttccgttgaatg	
2	K A K G T D Q Q N K E Y C S K E G N L L	
	*	
361	ttattgaatgtggagctcctcgatctcaaggacaacggagtgacctgtctactgctgtga	420
1	aataacttacacctcgaggagctagagttcctgttgccctcactggacagatgacgacact	
2	I E C G A P R S Q G Q R S D L S T A V S	
3	K N F T S S R S R L S L P T V Q R S S H	
	* P C R L S R D V A T	
421	gtaccttggttgagagcgggagtcgtggtgaccgttgagagcagcacctgtgaacgtttg	480
1	catggaacaacctctcgccctcagaccactggcaacgtctcgtcgtgggacattgcaaac	
2	T L L E S G S L V T V A E Q H P V T F V	
3	T G Q Q L A P T Q H G N C L L V R Y R K	
	L V K N S L P L R T V T A S C C G T V N	
481	tcagaaatttccgcgggctggctgaacttttgaaagtgagcgggaaaatgcagaagcgtg	540
1	agtcttttaaaggcggccgaccgacttgaaaactttcactcgcccttttacgtcttcgcac	
2	R N F R G L A E L L K V S G K M Q K R D	
3	D S I E A P Q S F K Q F H A P F H L L T	
	T L F K R P S A S S K F T L P F I C F R	
541	attggaagaccaatgtacacgtcattgtggggccacctgggtgtggtaaaagcaaattggg	600
4	taaccttctggttacatgtgcagtaacaccccggtggacccacaccattttcgtttaccc	
1	M Y T S L W G H L G V V K A N G	
2	W K T N V H V I V G P P G C G K S K W A	
3	I P L G I Y V D N H P W R P T T F A F P	
	S Q F V L T C T M	
601	ctgctaattttgcagacccggaaccacatactggaaaccacctagaaacaagtgggtggg	660
4	gacgattaaaacgtctgggccttttggtgtatgaccttgggtggatctttgttcaccaccc	
1	L L I L Q T R K P H T G N H L E T S G G	
2	A N F A D P E T T Y W K P P R N K W W D	
	S S I K C V R F G C V P F W R S V L P P	

FIG. 2A

4	661	atggttaccatggtgaagaagtgggtgttattgatgacttttatggctggctgccgtggg taccaatggtaccacttcttcaccaacaataactactgaaaataccgaccgacggcacc	720
1		M V T M V K K W L L L M T F M A G C R G	
2		G Y H G E E V V V I D D F Y G W L P W D	
		I T V M	
4	721	atgatctactgagactgtgtgatcgatatccattgactgtagagactaaaggtggaactg tactagatgactctgacacactagctataggttaactgacatctctgatttccaccttgac	780
1		M I Y *	
		D L L R L C D R Y P L T V E T K G G T V	
1	781	taccttttttggcccgagctattctgattaccagcaatcagaccccggttgaatggtact atggaaaaaacgggctcataagactaatggtcgttagtctggggcaaccttaccatga	840
		P F L A R S I L I T S N Q T P L E W Y S	
1	841	cctcaactgctgtcccagctgtagaagctctctatcgaggattacttcccttggtatttt ggagttgacgacagggctcgacatcttcgagagatagcctcctaataaggaaccataaaa	900
		S T A V P A V E A L Y R R I T S L V F W	
1	901	ggaagaatgctacaaaacaatccacggaggaagggggccagttcgtcaccctttccccc ccttcttacgatgttttgttaggtgccttcccccgggtcaagcagtggaagggggg	960
		K N A T K Q S T E E G G Q F V T L S P P	
5	961	catgccctgaatttccatatgaaataaattactgagtccttttttatcacttcgtaatggt gtacgggacttaaaggtatactttatttaatgactcagaaaaaatagtggaagcattacca	1020
1		M V	
		C P E F P Y E I N Y *	
5	1021	ttttattattcatttaggggttcaagtgggggtctttaagattaaattctctgaattgta aaaataataagtaaattcccaagttcacccccagaaaattctaatttaagagacttaacat	1080
6		F I I H L G F K W G V F K I K F S E L Y	
		* P E L P P D K L N F E R F Q	
5	1081	catacatgggttacacggatattgtagtcctggtcgattttactgttttcgaacgcagtg gtatgtaccaatgtgcctataacatcaggaccagcataaatgacaaaagcttgcgtaacg	1140
6		I H G Y T D I V V L V V F T V F E R S A	
		V Y M T V R I N Y D Q D Y K S N E F A T	
5	1141	cgaggcctacgtgggtccacatttccagaggtttgtagcctcagccaaagctgattccttt gctccgatgcaccaggtgtaaaggtctccaaacatcgagtcggtttcgactaaggaaa	1200
6		E A Y V V H I S R G L *	
		G L G V H D V N G S T Q L R L W L Q N R	
6	1201	tgttattttgggttgaagtaataatagtgagtcagaacaggtttgggtgtgaagtaac acaataaaccaaccttcattagttatcacctcagttcttgcacaaaccacacttcattg	1260
		K N N P Q F Y D I T S D L V P K P T F Y	
6	1261	gggagtggttaggagaaggggttgggggattgtatggcgggaggagtagtttacatatgggt ccctcaccatcctcttcccaaccccctaataccgcccctcctcatcaaatgtataccca	1320
		R S H Y S F P Q P I T H R S S Y N V Y P	
6	1321	cataggttagggctgtggcctttgttacaaagttatcatctaaaataacagcagtggaagc gtatccaatcccgaacccgaaacaatgtttcaatagtagattttattgtcgtcacctcg	1380
		D Y T L A T A K T V F N D D L I V A T S	

FIG. 2B

1381	ccactcccctatcacccctgggtgatgggggagcaaggccagaattcaaccttaacctttc	1440
6	ggtaggggatagtgggacccactacccctcggttcgggtcttaagttggaattggaaag	
	G V G R D G Q T I P S C P W F E V K V K	
1441	ttattctgtagtattcaaagggatatagagattttggttgggtccccctcccgggggaacaa	1500
6	aataagacatcataagtttcccatatctctaaaacaaccaggggggagggcccccttggt	
	R I R Y Y E F P I S I K N T G G G P P V	
1501	agtcgtcaatttttaaatctcatcatgtccacgcgccaggagggcggttgactgtggtac	1560
6	tcagcagttaaaatttagagtagtacaggtggcggtcctcccgcaacactgacaccatg	
	F D D I K F R M M D V A W S P T T V T T	
1561	gcttgacagtatatccgaaggtgcgggagagggcggtggtgaagatgccatttttccttc	1620
6	cgaactgtcatataggcttccacgcctctccgcccacaacttctacggtaaaaaggaag	
	R K V T Y G F T R S L R T N F I G N K R	
1621	tccaacggtagcggtggcgggggtggacgagccagggggcgggcgggaggatctggccaa	1680
6	aggttgccatcgccaccgccccacctgctcggtccccgcgcgcctcctagaccggtt	
	R W R Y R H R P H V L W P R R R L I Q G	
1681	gatggctgcggggcggtgtcttcttctgcggtaacgcctccttgatacgtcatagctg	1740
6	ctaccgacgccccgccacagaagaagacgccattgcggaggaacctatgcagtatcgac	
	L H S R P R H R R R R Y R R R P Y T M	
1741	aaaacgaaagaagtgcgctgtaagtatt	1800
	ttttgctttcttcacgcgacattcataa	

FIG. 2C

```

      10      20      30      40      50      60
MPSKKNRSGPQPHKRWVFTLNNPSEDERKKIRELPISLFDYFIVGEEGNEEGRTPHLQG
::::: ::::::::::::::::::::::::::::::::::::::: :::: ::::::::::
MPSKK---SGPQPHKRWVFTLNNPSEEEKNKIRELPISLFDYFVCGEEGLEEGRTPHLQG
      10      20      30      40      50

      70      80      90      100     110     120
FANFVKKQTFNKVKWYLGARCHIEKAKGTDQONKEYCSKEGNLLIECGAPRSQGQRSDLS
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
FANFAKKQTFNKVKWYFGARCHIEKAKGTDQONKEYCSKEGHILIECGAPRNQGRSDLS
      60      70      80      90      100     110

      130     140     150     160     170     180
TAVSTLLESGILVTVAQHPVTFVKNFRGLAELLKVSGKMQRDWKTNVHFIVGPPGCGK
::::::::: ::::: ::::::::::::::::::::::::::::::: :: ::::::::::
TAVSTLLETGSLVTVAEQFPVTVRNFRGLAELLKVSGKMQRDWKTAVHVIVGPPGCGK
      120     130     140     150     160     170

      190     200     210     220     230     240
SKWAANFANPETTYWKPPKNKWWDGYHGEKVVVIDDFYGWLPWDDLRLCDRYPLTVKTK
::::: ::::: ::::: ::::::::::::::::::::::::::::::::::::::::::::::
SQWARNFAEPRDTYWKPSRNKWWDGYHGEEVVVLDDFYGWLPWDDLRLCDRYPLTVETK
      180     190     200     210     220     230

      250     260     270     280     290
GGTVPFLARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATKQSTE-EGGQFV
::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::: :::::
GGTVPFLARSILITSNQAPQEWYSSTAVPAVEALYRRITTLQFWKTAGEQSTEVEGRFE
      240     250     260     270     280     290

300      310
TLSPPCPEFPYEINY
..... :::::
AVDPPCALFPYKINY
300      310

```

FIG. 3A

	10	20	30	40	50	
—	MKCTLVFQSRFCIFPLTFKSSASPRKFLTNVTGCCFATVTRIPLSNKVLTAVDRSLRCP-					
	:	:	:	:	:	:
	MTCTAVFQSRCCIFPLTFKSSASPRKFLTYVTGNCSATVTKDPVSKRVLTAVDRSLRFPW					
	10	20	30	40	50	60

—	FRGAPHSISMWPSLLQYSLFCWSVPFAFSMWQRAPKYHFTLLKVCFLAKFANPWR					
	70	80	90	100	110	

FIG. 3C

2025-11-26 14:26:26

PCV	ATTGTACATAAATAGTCACCCCTTACCACATAATTTGGGCTGTGGCTGCA-TTTTGAGCGGCATAGCCGAGCCCTGTGTCTCGACATTTGGTCTGGGTATTTAAATGGAGCCACAGCTGG	C G T CA GG TATTG G CC T - ATT A TG C A GT AC G C TCCAGA T G GCCTC A A	
412		C G T CA GG TATTG G CC T - ATT A TG C A GT AC G C TCCAGA T G GCCTC A A	
9741		C G T CA GG TATTG G CC T - ATT A TG C A GT AC G C TCCAGA T G GCCTC A A	
B9		C G T CA GG TATTG G CC T - ATT A TG C A GT AC G C TCCAGA T G GCCTC A A	
PCV	TTTCTTTTATTTATTTGGGTGGAAACCAATCAATTTGTTTGGTCCAGCTCAGGTTTGGGGTGAAGTACCTGGAGTGTAGGTAAAGGGCTGCCCTTATGTGTGGCGGAGGAGTAGTTAATA	C G G T GT A GGA A AA T T A G A G T GGG T A T C	
412		C G G T GT A GGA A AA T T A G A G T GGG T A T C	
9741		C G G T GT A GGA A AA T T A G A G T GGG T A T C	
B9		C G G T GT A GGA A AA T T A G A G T GGG T A T C	
PCV	TAGGGTCATAGGCCAAGTTGGTGGAGGGGTTACAAAGTTGGCATCCCAAGATAACAACAGTGGACCCACACCTCTTTGATTAGAGTGTAGGGTCTCTGGGGTAAATTCATATTTA	T T T G GCT CTTTT AT T A G G C T T C A C CCCTG GAG AA CC G ACC	
412		T T T G GCT CTTTT AT T A G G C T T C A C CCCTG GAG AA CC G ACC	
9741		T T T G GCT CTTTT AT T A G G C T T C A C CCCTG GAG AA CC G ACC	
B9		T T T G GCT CTTTT AT T A G G C T T C A C CCCTG GAG AA CC G ACC	
PCV	GCCTTTCTAATACGGTAGTATTGGAAAAGGTAGGGGTAGGGGTTGGTCCGCTGAGGGGGGAGGAACCTGCCGATGTGTAATTTGAGGTAGTTACATTCACAGATGGC--TGCGAGT	T T T T CA G TA AG TTTT C C CCC A CA G C T A T A C C TCAT CC CGC G G GT T C	
412		T T T T CA G TA AG TTTT C C CCC A CA G C T A T A C C TCAT CC CGC G G GT T C	
9741		T T T T CA G TA AG TTTT C C CCC A CA G C T A T A C C TCAT CC CGC G G GT T C	
B9		T T T T CA G TA AG TTTT C C CCC A CA G C T A T A C C TCAT CC CGC G G GT T C	
PCV	ATCCTCCTTTT-ATGGTGAGTACAAAATTCGTAGAAAGGCGGGAATTCAGAGATACCCGTCTTTTCGGCGCCATCTGTAAACGGTTTCTGAAGCGGGG-TGTGCAAAATATGGTCTTCTCCG	G GG A GC G CA ATA C G GGTCCGG G TG G AT T C TT T A G G ----- G GA G GCC G G GG GG	
412		G GG A GC G CA ATA C G GGTCCGG G TG G AT T C TT T A G G ----- G GA G GCC G G GG GG	
9741		G GG A GC G CA ATA C G GGTCCGG G TG G AT T C TT T A G G ----- G GA G GCC G G GG GG	
B9		G GG A GC G CA ATA C G GGTCCGG G TG G AT T C TT T A G G ----- G GA G GCC G G GG GG	
PCV	GAGGATGTTTCCAAAGATGGCTGCGGGGGGGTCTTCTTCTCGGTAACGGCTCCTTTGGCCACGTCATCCCTATATAAAGTGAAGAAGTGGCGCTGCTGTA-CTATT	C GG TGT AT AGCTG C- --- A	
412		C GG TGT AT AGCTG C- --- A	
9741		C GG TGT AT AGCTG C- --- A	
B9		C GG TGT AT AGCTG C- --- A	

FIG. 4B




FIG. 5

260727-1960260




FIG. 6

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS the specification of which

X is attached hereto
___ was filed on

and assigned Serial No. and was amended on .

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge and understand that I am an individual who has a duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §§ 1.56(a) and (b) which state:

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was

practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application. This invention was not in public use or on sale in the United States of America more than one year prior to this application. This invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to this application.

I hereby claim priority benefits under Title 35, United States Code § 119(e)(1) of any United States provisional application(s) for patent as indicated below and have also identified below any application for patent on this invention having a filing date before that of the application for patent on which priority is claimed:

<u>Application No.</u>	<u>Date of Filing</u> <u>(day/month/year)</u>	<u>Priority</u> <u>Claimed</u>
60/069,233	11 December 1997	Yes <u>X</u> No <u> </u>
60/069,750	16 December 1997	Yes <u>X</u> No <u> </u>

I hereby appoint the following attorneys and agents to prosecute that application and to transact all business in the Patent and Trademark Office connected therewith and to file, to prosecute and to transact all business in connection with all patent applications directed to the invention:

Roberta L. Robins, Reg. No. 33,208
Kenneth Barovsky, Reg. No. 36,442
Vandana Date, Reg. No. 38,675
Gary R. Fabian, Ph.D., Reg. No. 33,875

Address all correspondence to: Roberta L. Robins at

ROBINS & ASSOCIATES
90 Middlefield Road, Suite 200
Menlo Park, CA 94025

Address all telephone calls to: Roberta L. Robins at (650) 325-7812.

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature: _____

Date _____

Full Name of Inventor: Li WANG

Citizenship: Canada

Residence: Saskatoon, Saskatchewan, Canada S7H 1A4

Post Office Address: 8 - 2501 7th Street East, Saskatoon, Saskatchewan, Canada S7H 1A4

Signature: _____

Date _____

Full Name of Inventor: Lorne A. BABIUK

Citizenship: Canada

Residence: Saskatoon, Saskatchewan, Canada S7J 2Y1

Post Office Address: 245 E. Place, Saskatoon, Saskatchewan, Canada S7J 2Y1

Signature: _____

Date _____

Full Name of Inventor: Andrew A. POTTER

Citizenship: Canada

Residence: Saskatoon, Saskatchewan, Canada S7H 3S5

Post Office Address: 521 Dalhousie Crescent, Saskatoon, Saskatchewan, Canada S7H 3S5

Signature: _____

Date _____

Full Name of Inventor: Philip WILLSON

Citizenship: Canada

Residence: Saskatoon, Saskatchewan, Canada S7H 3C7

Post Office Address: 3 Oliver Crescent, Saskatoon, Saskatchewan, Canada S7H 3S5